Fate Therapeutics Price to Free Cash Flow Ratio 2012-2021 | FATE

Historical price to free cash flow ratio values for Fate Therapeutics (FATE) since 2012. For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
Fate Therapeutics Price to Free Cash Flow Ratio Historical Data
Date Stock Price TTM FCF per Share Price to FCF Ratio
2022-01-19 39.31 0.00
2021-09-30 59.27 $-1.60 0.00
2021-06-30 86.79 $-1.48 0.00
2021-03-31 82.45 $-0.50 0.00
2020-12-31 90.93 $-0.54 0.00
2020-09-30 39.97 $-0.64 0.00
2020-06-30 34.31 $-0.56 0.00
2020-03-31 22.21 $-1.40 0.00
2019-12-31 19.57 $-1.33 0.00
2019-09-30 15.53 $-1.13 0.00
2019-06-30 20.30 $-0.90 0.00
2019-03-31 17.57 $-0.78 0.00
2018-12-31 12.83 $-0.73 0.00
2018-09-30 16.29 $-0.80 0.00
2018-06-30 11.34 $-0.97 0.00
2018-03-31 9.76 $-0.98 0.00
2017-12-31 6.11 $-0.92 0.00
2017-09-30 3.96 $-0.90 0.00
2017-06-30 3.24 $-0.84 0.00
2017-03-31 4.55 $-0.88 0.00
2016-12-31 2.51 $-0.95 0.00
2016-09-30 3.12 $-1.04 0.00
2016-06-30 1.70 $-1.10 0.00
2016-03-31 1.80 $-0.71 0.00
2015-12-31 3.37 $-0.78 0.00
2015-09-30 5.33 $-0.76 0.00
2015-06-30 6.47 $-0.80 0.00
2015-03-31 4.89 $-1.19 0.00
2014-12-31 5.03 $-1.14 0.00
2014-09-30 5.10 $-3.47 0.00
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $3.879B $0.031B
Fate Therapeutics, Inc. is a biopharmaceutical company. The company focused on the discovery and development of adult stem cell modulators to treat hematologic malignancies, lysosomal storage disorders and muscular dystrophies. Fate Therapeutics, Inc. is headquartered in San Diego, California.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $144.033B 9.10
Bio-Rad Laboratories (BIO.B) United States $17.971B 36.47
QIAGEN (QGEN) Netherlands $11.044B 18.70
Biohaven Pharmaceutical Holding (BHVN) United States $7.729B 0.00
Emergent Biosolutions (EBS) United States $2.541B 9.14
Arcus Biosciences (RCUS) United States $2.414B 0.00
Myovant Sciences (MYOV) United Kingdom $1.374B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.167B 0.00
Zymeworks (ZYME) Canada $0.623B 0.00
Ambrx Biopharma (AMAM) United States $0.231B 0.00
SQZ Biotechnologies (SQZ) United States $0.214B 0.00
Enzo Biochem (ENZ) United States $0.161B 20.75